Neurocrine Biosciences (NBIX) Operating Margin: 2010-2021
Historic Operating Margin for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to 15.03%.
- Neurocrine Biosciences' Operating Margin rose 3217.00% to 15.03% in Q3 2021 from the same period last year, while for Sep 2021 it was 8.84%, marking a year-over-year decrease of 460.00%. This contributed to the annual value of 9.17% for FY2019, which is 99.00% up from last year.
- According to the latest figures from Q3 2021, Neurocrine Biosciences' Operating Margin is 15.03%, which was down 30.84% from 21.74% recorded in Q2 2021.
- Over the past 5 years, Neurocrine Biosciences' Operating Margin peaked at 40.57% during Q3 2019, and registered a low of -903.99% during Q2 2017.
- Over the past 3 years, Neurocrine Biosciences' median Operating Margin value was 19.37% (recorded in 2019), while the average stood at 8.94%.
- As far as peak fluctuations go, Neurocrine Biosciences' Operating Margin surged by 90,208bps in 2018, and later crashed by 5,770bps in 2020.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Operating Margin stood at 12.52% in 2017, then surged by 411bps to 16.63% in 2018, then surged by 335bps to 19.98% in 2019, then plummeted by 5,770bps to -17.14% in 2020, then surged by 3,217bps to 15.03% in 2021.
- Its Operating Margin was 15.03% in Q3 2021, compared to 21.74% in Q2 2021 and 13.31% in Q1 2021.